Adjusted EBITDA was $174 million, exceeding the high end of guidance, with a margin of 13.8%, down 30 basis points due to unfavorable currency impacts.
Gross profit margin improved by 10 basis points to 78%, driven by favorable pricing and lower inventory write-downs, partially offset by FX headwinds and input cost inflation.
Net income attributable to Herbalife was $49 million, with adjusted net income of $61 million and adjusted diluted EPS of $0.59, including an $0.11 FX headwind.
Net sales for Q2 2025 were $1.3 billion, down 1.7% year-over-year but flat on a constant currency basis.
Operating cash flow was strong at $96 million, and the company paid down $55 million in debt, maintaining a total leverage ratio of slightly under 3x as of June 30.